📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
535 analysed today
FollowTelegram
535
Today
149,936
All-time analysed
42,982
Positive
6,669
Negative
91,578
Neutral
8,639
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
386 announcements match the current filters (relevance ≥ 5).
Uniparts India Q3 Net Profit Surges to ₹469M; Declares ₹7 Interim Dividend
Uniparts India reported a robust performance for Q3 FY26, with standalone revenue from operations growing 43% YoY to ₹1,836.85 million. Net profit witnessed a massive jump to ₹469.27 million from ₹77.07 million in the corresponding quarter of the previous year. The company rewarded shareholders by declaring a second interim dividend of ₹7.00 per share. While the company faced an exceptional charge of ₹28.05 million due to new Labour Code provisions and a fire incident at its Ludhiana plant, the overall financial trajectory remains strongly positive.
Key Highlights
Standalone Net Profit for Q3 FY26 rose to ₹469.27 million, a significant increase from ₹77.07 million YoY.
Revenue from operations grew to ₹1,836.85 million compared to ₹1,281.74 million in Q3 FY25.
Declared a second interim dividend of ₹7.00 per equity share (70%) with a record date of February 16, 2026.
EPS for the quarter improved substantially to ₹10.40 from ₹1.71 in the previous year's quarter.
Recognized an exceptional expense of ₹28.05 million related to gratuity and leave liabilities under new Labour Codes.
👀 What to Watch
Investors should take note of the strong earnings growth and healthy dividend yield. The stock remains attractive given the sharp recovery in margins and robust revenue growth, though one should monitor the insurance settlement for the Ludhiana plant fire.
SPARC EGM Approves Preferential Warrant Issue to Promoters and New ESOP Scheme 2026
Sun Pharma Advanced Research Company (SPARC) held an Extraordinary General Meeting on February 9, 2026, to seek approval for three key special resolutions. The primary agenda included the issuance of convertible warrants on a preferential basis to members of the Promoter Group, signaling strong internal backing. Additionally, the company sought approval for the 'SPARC Employees Stock Option Scheme 2026' to be implemented for employees of the company and its subsidiaries/associates. These moves are aimed at securing long-term capital for R&D and retaining key talent in a competitive clinical research environment.
Key Highlights
Proposed issuance of convertible warrants on a preferential basis to the Promoter Group to raise capital.
Introduction of the 'SPARC Employees Stock Option Scheme 2026' for employee incentivization.
Extension of ESOP benefits to employees of subsidiary, holding, and associate companies.
Remote e-voting concluded on February 8, 2026, with final results expected within two working days.
The meeting was chaired by Mr. Dilip Shanghvi and conducted via video conferencing.
👀 What to Watch
Investors should view the promoter participation in the warrant issue as a sign of confidence in the company's long-term R&D pipeline. Monitor the upcoming disclosure of voting results and the specific pricing details of the warrants to assess potential equity dilution.
SPARC Q3 Net Loss Widens to ₹80.57 Cr; Receives USFDA Priority Review Voucher for Sezaby
SPARC reported a consolidated net loss of ₹80.57 crore for the quarter ended December 31, 2025, as revenue from operations declined 43% YoY to ₹8.45 crore. The results were further impacted by a one-time exceptional charge of ₹12.36 crore due to the implementation of New Labour Codes. A major positive development is the USFDA's grant of a Rare Pediatric Disease Priority Review Voucher (PRV) for Sezaby® in February 2026, which is a highly valuable tradable asset. The company remains reliant on promoter support to maintain its 'Going Concern' status amid continued cash losses.
Key Highlights
Revenue from operations fell to ₹8.45 crore in Q3 FY26 from ₹14.91 crore in Q3 FY25.
Net loss widened to ₹80.57 crore for the quarter, including a ₹12.36 crore exceptional item for labor code adjustments.
USFDA granted a tradable Rare Pediatric Disease Priority Review Voucher (PRV) for Sezaby® on February 03, 2026.
Finance costs surged to ₹6.78 crore (standalone) from ₹2.77 crore in the corresponding quarter last year.
Company maintains 'Going Concern' status based on a financial support letter from its promoter group entity.
👀 What to Watch
Investors should closely track the potential monetization or sale of the Priority Review Voucher (PRV), which could provide a significant non-dilutive cash infusion. While the operational losses are concerning, the PRV and promoter backing provide a temporary safety net for this R&D-focused entity.
SPARC Q3 Net Loss Widens to ₹80.57 Cr; Receives Valuable USFDA Priority Review Voucher
SPARC reported a sharp decline in revenue to ₹8.45 crore for Q3 FY26, down from ₹14.91 crore in the previous year. The standalone net loss widened to ₹80.57 crore, further impacted by a one-time exceptional charge of ₹12.36 crore related to new labor code compliance. A major positive development is the USFDA's grant of a tradeable Priority Review Voucher (PRV) for Sezaby®, which represents a significant potential cash inflow if sold. The company remains a 'going concern' primarily due to continued financial support from its promoter group.
Key Highlights
Revenue from operations dropped 43% YoY to ₹845 Lakhs in Q3 FY26.
Standalone net loss widened to ₹8,057 Lakhs from ₹7,971 Lakhs in the same quarter last year.
Recognized an exceptional cost of ₹1,236 Lakhs due to the implementation of New Labour Codes.
USFDA granted a Rare Pediatric Disease Priority Review Voucher (PRV) for Sezaby® on February 3, 2026.
Company continues to incur cash losses but maintains 'Going Concern' status via promoter support.
👀 What to Watch
Investors should monitor the potential sale or monetization of the newly granted PRV, which could significantly improve the balance sheet. However, the core R&D business remains high-risk and loss-making, requiring a long-term perspective and high risk appetite.
PARKHOTELS Q3 Revenue Hits Record ₹200 Cr; PAT Drops 25% Amid Expansion Costs
Apeejay Surrendra Park Hotels reported its best-ever Q3 revenue of ₹200 crore, marking a 13% YoY growth driven by strong demand and an 11% increase in Average Room Rates (ARR) to ₹9,310. While operating EBITDA grew by 10% to ₹71 crore, PAT declined by 25% to ₹24 crore, impacted by higher finance and depreciation costs following recent acquisitions. The company maintains industry-leading occupancy at 90% and is launching a major serviced residence project in Kolkata expected to generate ₹300-350 crore in cash flow over the next three years. The retail brand Flurys continues to scale rapidly, recording 19% growth in Q3.
Key Highlights
Consolidated revenue for Q3 FY26 crossed ₹200 crore for the first time, a 13% YoY increase.
Average Room Rate (ARR) grew 11% YoY to ₹9,310, while RevPAR increased 9% to ₹8,347.
Acquisition of Malabar House and Purity completed in December 2025 for a total cost of ₹64 crore.
Retail brand Flurys recorded 19% revenue growth and achieved a record single-day sale of ₹1 crore on December 24th.
Net Debt remains low with a Debt/Equity ratio of 0.11 and total Net Debt of ₹154.65 crore.
👀 What to Watch
Investors should focus on the company's ability to translate strong topline growth and high occupancy into bottom-line recovery as expansion costs stabilize. The upcoming monetization of the Kolkata serviced residences and the aggressive scaling of the Flurys brand are significant value-unlocking catalysts to monitor.
Parag Milk Foods Q3 FY26: Revenue Hits Record ₹1,013 Cr; New-Age Biz Crosses ₹100 Cr Mark
Parag Milk Foods reported its highest-ever quarterly revenue of ₹1,013 crore, marking a 14% YoY growth driven by strong performance in core categories and a 123% surge in its new-age business. While volumes grew by 8%, EBITDA margins contracted to 7.6% from 9.0% due to a 20% YoY spike in milk procurement prices. The New Age segment, comprising Avvatar and Pride of Cows, now contributes 9% to total revenue, crossing the ₹100 crore quarterly milestone for the first time. Despite inflationary pressures, the company maintained sequential gross margins through calibrated pricing and an improved product mix.
Key Highlights
Highest ever quarterly revenue of ₹1,013 Cr, up 14% YoY with 8% volume growth.
New-age business (Avvatar & Pride of Cows) revenue surged 123% YoY to ₹102 Cr in Q3.
Core categories (Ghee, Cheese, Paneer) grew 21% in value and 12% in volume, contributing 64% of revenue.
EBITDA margin contracted to 7.6% (vs 9.0% YoY) primarily due to 20% YoY milk price inflation.
Maintains dominant market position with 22% share in branded cow ghee and 35% share in cheese.
👀 What to Watch
Investors should focus on the rapid scaling of the high-margin New Age business and the company's ability to maintain sequential margins despite milk price volatility. The stock remains a strong play on dairy premiumization, though short-term margin pressure from raw material inflation warrants a watch.
Parag Milk Foods Q3 FY26: Revenue Hits Record ₹1,013 Cr; New Age Business Surges 123%
Parag Milk Foods achieved its highest-ever quarterly revenue of ₹1,013 crore in Q3 FY26, a 14% YoY increase supported by 8% volume growth. The company's 'New Age' segment, including Avvatar and Pride of Cows, crossed the ₹100 crore quarterly milestone for the first time, growing 123% YoY. However, EBITDA margins faced pressure, declining to 7.6% from 9.0% a year ago, primarily due to a 20% YoY spike in milk procurement prices. Despite this, the company maintained market leadership in core categories like Ghee (22% share) and Cheese (35% share).
Key Highlights
Highest ever quarterly revenue of ₹1,013 Cr, up 14% YoY with 8% volume growth.
New Age business revenue grew 123% YoY to ₹102 Cr, increasing its revenue contribution to 9%.
Core categories (Ghee, Cheese, Paneer) saw 21% value growth and 12% volume growth.
EBITDA margin contracted to 7.6% from 9.0% YoY due to 20% inflation in milk prices reaching ₹40/litre.
9M FY26 PAT (before exceptional items) rose 17% YoY to ₹109 Cr.
👀 What to Watch
The rapid scaling of high-margin 'New Age' brands is a significant long-term positive that helps offset raw material volatility. Investors should monitor if milk prices stabilize, which could lead to a strong margin recovery given the robust top-line momentum.
Parag Milk Foods Q3 FY26: Revenue Crosses INR 1,000 Cr Mark, Up 14% YoY; PAT Down 18%
Parag Milk Foods reported its highest-ever quarterly revenue of INR 1,013 crore, representing a 14% YoY growth driven by strong performance in core categories and a 123% surge in its New Age Business. However, profitability was pressured by a 20% YoY increase in raw milk prices, leading to a 140 bps contraction in EBITDA margins to 7.6%. While reported PAT fell 18% to INR 30 crore, the adjusted PAT (before exceptional items) remained relatively stable at INR 35 crore. The company successfully maintained sequential gross margins at 25.9% despite rising input costs through pricing strategies and a better product mix.
Key Highlights
Achieved highest-ever quarterly revenue of INR 1,013 Cr, a 14% YoY increase with 8% volume growth.
New Age Business (Avvatar and Pride of Cows) recorded 123% YoY growth, crossing INR 100 Cr in quarterly revenue for the first time.
Core categories including Ghee, Cheese, and Paneer witnessed 12% volume growth and 21% value growth YoY.
EBITDA margins contracted to 7.6% from 9.0% YoY due to raw milk prices rising 20% YoY to INR 40/litre.
9M FY26 PAT grew 11% YoY to INR 103 Cr, while adjusted PAT for the same period grew 17% YoY to INR 109 Cr.
👀 What to Watch
Investors should monitor the company's ability to sustain volume growth in core categories while navigating high milk price inflation. The rapid scaling of the high-margin 'Avvatar' brand is a positive long-term driver, but near-term margin pressure from commodity costs remains a key watchpoint.
Parag Milk Foods Q3 FY26 Revenue Up 13% YoY to ₹984 Cr; PAT Flat at ₹34.6 Cr
Parag Milk Foods reported a 13.3% YoY growth in standalone revenue for Q3 FY26, reaching ₹984.19 crore. Net profit remained nearly stagnant at ₹34.55 crore compared to ₹34.18 crore in the previous year, largely due to a one-time exceptional charge of ₹5.39 crore for labor code provisions. While the 9-month performance remains strong with a 34.6% PAT growth, the sequential (QoQ) profit saw a sharp 38% decline from ₹55.70 crore in Q2 FY26. Rising material costs, which grew from ₹600 crore to ₹705 crore YoY, continue to pressure quarterly margins.
Key Highlights
Revenue from operations increased 13.3% YoY to ₹984.19 crore in Q3 FY26.
Standalone PAT for the quarter stood at ₹34.55 crore, including a ₹5.39 crore exceptional hit.
9-month FY26 PAT surged 34.6% to ₹122.60 crore compared to ₹91.09 crore in 9M FY25.
Finance costs decreased significantly to ₹18.64 crore from ₹23.50 crore in the same quarter last year.
Cost of materials consumed rose to ₹704.79 crore in Q3 FY26 from ₹600.24 crore in Q3 FY25.
👀 What to Watch
Investors should focus on the company's ability to manage rising raw material costs which are impacting quarterly margins. While the long-term 9-month growth trajectory is positive, the sequential dip in profitability suggests a need for caution regarding short-term operational headwinds.
Parag Milk Foods Q3 FY26 Standalone PAT at ₹34.55 Cr; Revenue up 13.3% YoY to ₹984.19 Cr
Parag Milk Foods reported a 13.3% YoY growth in standalone revenue for Q3 FY26, reaching ₹984.19 crore. However, net profit remained nearly flat YoY at ₹34.55 crore and saw a significant sequential decline from ₹55.70 crore in Q2 FY26. The bottom line was impacted by a one-time exceptional charge of ₹5.39 crore related to new Government Labour Code provisions for employee benefits. Despite the quarterly pressure, the nine-month (9M FY26) performance remains strong with PAT rising 34.6% YoY to ₹122.60 crore.
Key Highlights
Standalone Revenue from operations grew 13.3% YoY to ₹984.19 crore in Q3 FY26.
Standalone Net Profit for the quarter stood at ₹34.55 crore, compared to ₹34.18 crore in the previous year's corresponding quarter.
Recognized a one-time exceptional expense of ₹5.39 crore due to the implementation of new unified Labour Codes.
9M FY26 performance shows robust growth with total income reaching ₹2,823.56 crore and PAT up 34.6% YoY.
Finance costs for the quarter decreased to ₹18.64 crore from ₹23.50 crore in Q3 FY25, indicating improved debt management.
👀 What to Watch
Investors should monitor the company's ability to maintain margins as the QoQ profit decline suggests rising operational costs despite steady revenue. The long-term growth trajectory for the 9-month period remains positive, but short-term volatility in raw material costs and the impact of new labour regulations should be watched.
Park Hotels Q3 Standalone Revenue Grows 9% YoY to ₹187.6 Cr; PAT at ₹24.7 Cr
Apeejay Surrendra Park Hotels reported a 9.3% YoY increase in standalone revenue from operations to ₹187.61 crore for Q3 FY26. While EBITDA grew to ₹68.78 crore from ₹64.41 crore YoY, Net Profit (PAT) declined to ₹24.67 crore from ₹31.90 crore due to higher depreciation, finance costs, and tax expenses. The company is aggressively expanding, having concluded the acquisition of Zillion Hotels in Mumbai for ₹224.76 crore and Fisherman's Grove in Kerala for ₹20.50 crore. An exceptional loss of ₹1.40 crore was recorded during the quarter related to the implementation of new Government Labour Codes.
Key Highlights
Standalone Revenue from operations increased 9.3% YoY to ₹187.61 crore.
EBITDA improved to ₹68.78 crore compared to ₹64.41 crore in the same quarter last year.
Acquired Zillion Hotels and Resorts (Mumbai) for ₹224.76 crore to strengthen presence in the Juhu market.
Acquired 100% stake in Fisherman's Grove Resorts (Kerala) for ₹20.50 crore.
Net Profit (PAT) stood at ₹24.67 crore, impacted by a ₹1.40 crore exceptional charge for labor code compliance.
👀 What to Watch
Investors should focus on the company's aggressive inorganic growth strategy and how the newly acquired Mumbai and Kerala assets contribute to the bottom line in coming quarters. While operational margins remain steady, the impact of increased depreciation and finance costs from acquisitions on net profitability warrants a cautious watch.
Park Hotels Q3 Standalone Revenue Up 9% YoY to ₹187.6 Cr; PAT Declines to ₹24.7 Cr
Apeejay Surrendra Park Hotels reported a 9.2% YoY increase in standalone revenue from operations to ₹187.61 crore for Q3 FY26. However, Profit After Tax (PAT) saw a YoY decline of 22.6%, falling to ₹24.67 crore, primarily due to higher operating expenses and a ₹1.40 crore exceptional charge related to new labour codes. On a sequential basis, performance improved significantly with revenue and PAT growing 17.7% and 59% respectively. The company also highlighted strategic acquisitions in Mumbai and Kerala to bolster its hospitality portfolio.
Key Highlights
Standalone revenue grew 9.2% YoY to ₹187.61 crore in Q3 FY26 compared to ₹171.71 crore in Q3 FY25.
Profit After Tax (PAT) stood at ₹24.67 crore, a decrease from ₹31.90 crore in the previous year's corresponding quarter.
Operating expenses rose to ₹120.28 crore from ₹109.67 crore YoY, impacting overall margins.
The company completed the acquisition of Zillion Hotels (Mumbai) for ₹224.76 crore and Fisherman’s Grove (Kerala) for ₹20.50 crore.
An exceptional item of ₹1.40 crore was recognized during the quarter due to the impact of new Government Labour Codes.
👀 What to Watch
Investors should monitor the integration and occupancy rates of the newly acquired properties in Mumbai and Kerala as they are key to future revenue growth. While sequential growth is strong, the YoY margin compression suggests a need to watch cost management closely.
Apar Industries Q3 FY26 PAT Rises 19.4% to ₹209 Cr; Conductor EBITDA/MT Hits Record ₹44,195
Apar Industries reported a 16.2% YoY growth in consolidated revenue to ₹5,480 crores for Q3 FY26, driven by a strong 30% growth in the domestic market. Despite a slowdown in US exports due to Section 232 tariffs, the Conductor segment achieved a record EBITDA of ₹44,195 per metric ton due to a superior product mix. The company recognized an exceptional loss of ₹25 crores for labor code provisions but still managed a 19.4% increase in PAT to ₹209 crores. Management noted a recovery in US cable orders with ₹500 crores booked in Q3, signaling a potential rebound in Q4.
Key Highlights
Consolidated revenue grew 16.2% YoY to ₹5,480 crores, while 9-month PAT reached an all-time high of ₹723 crores.
Conductor segment EBITDA/MT surged to ₹44,195 from ₹29,593 YoY, supported by a 44.2% premium product mix.
Domestic revenue across segments grew 30% YoY, offsetting an 11.2% decline in total exports.
Cable segment saw a 65% drop in US revenue in Q3, but secured ₹500 crores in new orders for execution in Q4.
Exceptional provision of ₹25 crores made for past service costs related to the new labor code.
👀 What to Watch
Investors should monitor the sustainability of the high conductor margins and the execution of the new ₹500 crore US cable order book. The company remains a key beneficiary of India's renewable energy push and global grid modernization.
Paradeep Phosphates Amends MOA to Enter Power Generation and Distribution Business
Paradeep Phosphates Limited has received shareholder approval via a special resolution to amend its Memorandum of Association (MOA). The amendment adds a new object clause allowing the company to generate, distribute, and sell electrical power from conventional and non-conventional sources, including waste heat recovery systems. This strategic move enables the company to monetize surplus power by selling it to state utilities and open market buyers, potentially creating a new revenue stream. The resolution was officially passed through a postal ballot concluded on February 02, 2026.
Key Highlights
Special Resolution passed on February 02, 2026, to alter the Company's Object Clause.
New sub-clause (iv) inserted to permit dealing in electrical power and energy from various sources.
Specific inclusion of waste heat recovery systems to optimize industrial efficiency.
Authorization to sell surplus power to State utilities and open market buyers under applicable laws.
Restructuring of MOA Clause III to align with modern regulatory titling and numbering standards.
👀 What to Watch
Investors should view this as a positive step toward operational efficiency and revenue diversification. Monitor upcoming capital expenditure plans related to power infrastructure or waste heat recovery projects.
Paradeep Phosphates Q3 Net Profit Falls 13% to ₹182 Cr; 9M Profit Jumps 71.6% Post MCFL Merger
Paradeep Phosphates (PPL) reported a mixed Q3 FY26 with total income rising 14.9% YoY to ₹5,779.7 crore, but net profit declining 13% to ₹182.1 crore due to higher material costs. The 9-month (9M) performance was significantly stronger, with net profit surging 71.6% to ₹840.7 crore and EBITDA growing 44.7% to ₹1,816.6 crore. The completion of the MCFL merger in October 2025 has expanded PPL's capacity to 3.7 MMTPA and strengthened its presence in Southern India. The company is now targeting a total capacity of 5.0 MMTPA by FY29 while pursuing 100% backward integration for phosphoric acid.
Key Highlights
9M FY26 Net Profit rose 71.6% YoY to ₹8,407 million; Total Income grew 34.1% to ₹172,311 million.
Q3 FY26 Net Profit declined 13% YoY to ₹1,821 million despite a 14.9% rise in Total Income.
Total fertilizer sales volume for 9M FY26 reached 3.36 million MT, a 16.9% YoY increase.
MCFL merger completed in Oct 2025, adding 23% capacity and diversifying the product basket with Urea.
Capex plan underway to expand granulation capacity to 5.0 MMTPA by FY29, funded via internal accruals and debt.
👀 What to Watch
While Q3 saw margin pressure, the strong 9M growth and MCFL merger integration provide a solid foundation for long-term expansion. Investors should monitor the progress of backward integration projects at the Paradeep plant, which are critical for hedging global raw material price volatility.
Paradeep Phosphates Shareholders Approve Borrowing Limit Increase and New Board Appointments
Paradeep Phosphates Limited (PPL) has successfully passed five key resolutions through a postal ballot with overwhelming shareholder support. A significant resolution to increase borrowing limits and create charges on company assets was passed with 99.52% approval, providing the company with enhanced financial flexibility for future requirements. Additionally, shareholders ratified the appointment of two new directors and approved an alteration to the company's Memorandum of Association. The high voter turnout of 79.6% indicates strong alignment between the management and its large institutional and promoter base.
Key Highlights
Resolution to increase borrowing limits and create asset charges passed with 99.52% majority.
Appointment of Mrs. Ruchira Kamboj as Non-Executive Independent Director approved with 99.64% votes.
Alteration of the Memorandum of Association (MOA) object clause received 99.99% shareholder approval.
Total voting participation stood at 79.60%, representing 82.62 crore shares out of 103.79 crore total shares.
Appointment of Mr. Akshay Poddar as Non-Executive Director cleared with 97.74% support.
👀 What to Watch
Investors should monitor the company's upcoming debt-raising activities and capital expenditure plans following the approved increase in borrowing limits. The high approval rates for all resolutions signal strong confidence in the current management and the company's strategic direction.
SPARC Receives Valuable US FDA Priority Review Voucher for Sezaby® Approval
Sun Pharma Advanced Research Company (SPARC) has been granted a Rare Pediatric Disease Priority Review Voucher (PRV) by the US FDA following the approval of Sezaby® for neonatal seizures. This voucher is a highly valuable asset that can be used to expedite the review of a future drug application or sold to another pharmaceutical company. Historically, PRVs have commanded market prices between $90 million and $110 million, representing a significant potential non-dilutive cash inflow. This milestone enhances SPARC's strategic flexibility and validates its R&D capabilities in the rare pediatric disease space.
Key Highlights
US FDA grants Rare Pediatric Disease Priority Review Voucher (PRV) associated with Sezaby® approval.
Sezaby® is a specialized formulation of phenobarbital sodium for treating neonatal seizures.
The PRV is a tradable asset that can be sold to third parties for significant capital or used for future priority reviews.
Receipt of the voucher provides SPARC with additional liquidity to accelerate its clinical pipeline.
The announcement confirms the successful regulatory pathway for SPARC's pediatric innovation.
👀 What to Watch
Investors should monitor for any future announcements regarding the sale of this voucher, which could provide a substantial one-time cash boost. This development strengthens the company's balance sheet without equity dilution.
Paradeep Phosphates Q3 Revenue Up 15% to ₹5,749 Cr; 9M PAT Surges 71% to ₹841 Cr
Paradeep Phosphates (PPL) delivered a robust performance for Q3 FY26, with revenue growing 15% YoY to ₹5,749 crore and EBITDA rising 5% to ₹503 crore. The nine-month (9M) performance was particularly strong, with PAT surging 71% YoY to ₹841 crore and revenue increasing 34% to ₹17,124 crore. Growth was primarily driven by higher sales volumes in value-added NPK grades (up 30%) and TSP (up 107%). The company is also progressing on its backward integration strategy, expanding Phos Acid capacity to 0.7 MMTPA to improve long-term margins.
Key Highlights
9M FY26 PAT increased by 71% YoY to ₹841 crore, while EBITDA rose 45% to ₹1,817 crore.
Q3 FY26 Revenue from operations grew 15% YoY to ₹5,749 crore with production volumes up 13%.
NPK sales volumes grew 30% YoY in 9M to 17.51 lakh tonnes; TSP sales surged 107% to 2.43 lakh tonnes.
Phos Acid expansion from 0.5 to 0.7 MMTPA is underway to achieve 100% backward integration across sites.
Credit rating upgraded to AA, reflecting improved fundamentals and optimizing cost of capital for capex.
👀 What to Watch
The strong volume growth in high-margin products and the move toward 100% backward integration are significant positives for long-term profitability. Investors should monitor the progress of the Phos Acid expansion and granulation debottlenecking as key drivers for future earnings.
Paradeep Phosphates Q3 PAT at ₹182 Cr; N Suresh Krishnan Re-appointed as MD & CEO
Paradeep Phosphates reported a 15.2% year-on-year increase in revenue to ₹5,748.67 crore for Q3 FY26. However, quarterly net profit declined to ₹182.05 crore from ₹209.28 crore in the previous year, primarily due to an exceptional item of ₹41.30 crore. On a nine-month basis, the company showed robust growth with PAT reaching ₹841.24 crore, up from ₹490.66 crore. The board also confirmed key leadership roles, re-appointing N Suresh Krishnan as MD & CEO and appointing K K Rajeev Nambiar as Joint MD.
Key Highlights
Revenue from operations increased to ₹5,748.67 crore in Q3 FY26 vs ₹4,989.55 crore in Q3 FY25.
Net profit for the quarter stood at ₹182.05 crore, impacted by a ₹41.30 crore exceptional charge.
9M FY26 PAT surged 71.4% to ₹841.24 crore compared to ₹490.66 crore in the previous year period.
N Suresh Krishnan re-appointed as MD & CEO for 3 years effective February 16, 2026.
Financial results reflect the merger with Mangalore Chemicals & Fertilizers Limited (MCFL) effective April 1, 2024.
👀 What to Watch
Investors should focus on the strong nine-month growth trajectory and the successful integration of MCFL, while keeping an eye on the impact of exceptional items on quarterly margins. The leadership continuity is a positive sign for long-term strategic execution.
Paradeep Phosphates Q3 PAT at ₹182 Cr; Appoints K K Rajeev Nambiar as Joint MD
Paradeep Phosphates reported a 15.2% YoY increase in standalone revenue to ₹5,748.67 crore for Q3 FY26. However, quarterly net profit declined to ₹182.05 crore from ₹209.28 crore in the previous year, primarily due to an exceptional item of ₹41.30 crore. The nine-month performance remains robust, with PAT surging 71% to ₹841.24 crore compared to ₹490.66 crore in the same period last year. The company also announced leadership changes, including the re-appointment of N Suresh Krishnan as MD and the appointment of K K Rajeev Nambiar as Joint MD.
Key Highlights
Revenue from operations for Q3 FY26 stood at ₹5,748.67 crore, up from ₹4,989.55 crore YoY.
Net profit for the nine months ended Dec 2025 reached ₹841.24 crore, a significant jump from ₹490.66 crore YoY.
Quarterly PAT was impacted by an exceptional charge of ₹41.30 crore, resulting in a YoY dip to ₹182.05 crore.
Mr. N Suresh Krishnan re-appointed as MD for 3 years; Mr. K K Rajeev Nambiar appointed as Joint MD starting April 2026.
Financial results incorporate the retrospective impact of the MCFL merger effective from April 1, 2024.
👀 What to Watch
Investors should look past the quarterly PAT dip caused by exceptional items and focus on the strong nine-month growth and successful MCFL integration. The strengthening of the top management team suggests a focus on long-term operational excellence.
